Equities analysts expect United Therapeutics Corporation (NASDAQ:UTHR) to report earnings of $4.00 per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for United Therapeutics Corporation’s earnings, with estimates ranging from $3.47 to $4.25. United Therapeutics Corporation posted earnings of $3.50 per share during the same quarter last year, which would indicate a positive year over year growth rate of 14.3%. The business is scheduled to report its next earnings report on Thursday, October 26th.

According to Zacks, analysts expect that United Therapeutics Corporation will report full year earnings of $10.42 per share for the current year, with EPS estimates ranging from $8.88 to $11.72. For the next year, analysts anticipate that the firm will post earnings of $11.48 per share, with EPS estimates ranging from $10.14 to $13.16. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for United Therapeutics Corporation.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. The firm had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.42 earnings per share.

UTHR has been the subject of several research reports. Cowen and Company reissued a “hold” rating and set a $121.00 price target on shares of United Therapeutics Corporation in a report on Wednesday, April 26th. Wedbush reissued an “outperform” rating and set a $213.00 price target (down from $229.00) on shares of United Therapeutics Corporation in a report on Thursday, April 27th. Jefferies Group LLC reissued an “underperform” rating and set a $105.00 price target (down from $116.00) on shares of United Therapeutics Corporation in a report on Friday, April 28th. ValuEngine cut United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, June 2nd. Finally, BidaskClub raised United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, June 9th. Six investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $134.50.

TRADEMARK VIOLATION WARNING: “Analysts Expect United Therapeutics Corporation (UTHR) Will Post Earnings of $4.00 Per Share” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.watchlistnews.com/analysts-expect-united-therapeutics-corporation-uthr-will-post-earnings-of-4-00-per-share/1510807.html.

United Therapeutics Corporation (NASDAQ:UTHR) traded down 1.50% during mid-day trading on Friday, hitting $129.10. The stock had a trading volume of 557,656 shares. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of 14.97 and a beta of 1.51. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The stock’s 50 day moving average price is $130.38 and its 200 day moving average price is $134.34.

United Therapeutics Corporation declared that its Board of Directors has initiated a stock buyback plan on Thursday, April 27th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to buy up to 4.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

In other news, Director Christopher Causey sold 590 shares of United Therapeutics Corporation stock in a transaction on Thursday, July 6th. The stock was sold at an average price of $132.61, for a total value of $78,239.90. Following the transaction, the director now owns 3,875 shares in the company, valued at approximately $513,863.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,265 shares of United Therapeutics Corporation stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $119.40, for a total value of $151,041.00. Following the completion of the transaction, the chief executive officer now owns 1,405 shares in the company, valued at approximately $167,757. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,649 shares of company stock worth $3,192,423. Corporate insiders own 7.80% of the company’s stock.

A number of large investors have recently modified their holdings of the company. HPM Partners LLC raised its stake in shares of United Therapeutics Corporation by 0.8% in the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after buying an additional 15 shares in the last quarter. First Allied Advisory Services Inc. raised its stake in shares of United Therapeutics Corporation by 0.4% in the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after buying an additional 19 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its stake in shares of United Therapeutics Corporation by 0.3% in the first quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock worth $1,712,000 after buying an additional 40 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of United Therapeutics Corporation by 1.4% in the second quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock worth $411,000 after buying an additional 45 shares in the last quarter. Finally, Argent Capital Management LLC raised its stake in shares of United Therapeutics Corporation by 2.4% in the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock worth $343,000 after buying an additional 60 shares in the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Get a free copy of the Zacks research report on United Therapeutics Corporation (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.